Lung Adenocarcinoma: From Genome Changes to New Therapies
Official title: Lung Adenocarcinoma: From Genome Alterations to Therapeutic Discovery
Funded at Dana-Farber Cancer Inst · NIH-11380915 · Data updated 2026-11-12
This NIH grant supports research on lung adenocarcinoma to better understand its genome changes and translate that knowledge into better diagnosis and treatments for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | August 1, 2015 |
| Project end | July 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $1,044,418 |
| NIH project number | 5R35CA197568-13 |
| Project ID | NIH-11380915 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with lung adenocarcinoma or those at risk who could benefit from advances in genomic-guided diagnosis and treatment.
✕Less likely to help
Patients with very advanced or comorbid conditions may not experience direct benefit from experimental genomic approaches.
What this research studies
Researchers at Dana-Farber are studying the genome changes in lung adenocarcinoma to uncover how these alterations drive cancer and how they can be targeted with new therapies. The project integrates genomic discoveries, model systems, and approaches that could lead to more precise diagnostics and personalized treatments for patients with this deadly disease. The work involves analyzing somatic genome alterations, studying oncogenic mutations like BRAF and EGFR, and using genomically engineered models to explore new therapeutic strategies. The goal is to translate genomic insights into improved outcomes and options for people affected by lung cancer.
Why it matters
Potential benefit: If successful, patients with lung adenocarcinoma could receive more effective, targeted therapies guided by their tumor’s genetic makeup.
How similar studies have gone: Previous genome-based discoveries in lung cancer have guided targeted therapies (e.g., EGFR, BRAF) and informed clinical decisions; this work builds on those successes with expanded genomic insight.
Where this research is happening
-
Dana-Farber Cancer Inst
Boston, United States Active
Researchers
- Principal investigator: Meyerson, Matthew L. — Dana-Farber Cancer Inst
- Study coordinator: Meyerson, Matthew L.
Related research
Other NIH-funded projects on the same topics.
-
Understanding a highly flexible cell state in lung cancer that worsens outcomes
A doctor-scientist at Cedars-Sinai wants to learn how a highly adaptable lung cancer cell state drives disease progression and resistance to therapy, using models that resemble human tumors.
-
Breaking cytokine loops in LKB1-mutant lung cancer and the immune system
A researcher at NYU School of Medicine is studying why a common lung cancer subtype with a specific mutation doesn’t respond well to current immunotherapy, with the aim of finding new ways to improve treatment.
-
Understanding how lung cancer and immune cells influence each other in early lung cancer development
A study looks at how lung cells and immune cells change together as early lung cancer (lung adenocarcinoma) develops, with the goal of finding points to intervene early.
-
Targeting a cancer pathway to stop metastasis in SMARCA4-deficient lung cancer
This grant aims to understand and interrupt a key pathway that drives spread of a specific type of lung cancer in people whose tumors have SMARCA4 mutations.
-
Combining imaging and biopsy genes to spot aggressive vs. slow-growing early lung cancer before surgery
Aimed at people with early-stage lung adenocarcinoma, this project tests a combined imaging and biopsy gene‑marker approach to better predict tumor aggressiveness before surgery.
-
Aberrant glycogen in lung adenocarcinoma tumor growth
A new project will study how abnormal glycogen in lung adenocarcinoma tumors may drive cancer growth and help identify targets for future therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.